Last reviewed · How we verify
Multivirus-specific T cells Dose Level 3
Multivirus-specific T cells Dose Level 3 is a Biologic drug developed by AlloVir. It is currently in Phase 1 development.
Multivirus-specific T cells Dose Level 3 are being studied in clinical trials for the treatment and prevention of viral infections, including Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, and others. These T cells are part of the ARMS study, which aims to administer rapidly generated multivirus-specific cytotoxic T-lymphocytes for prophylaxis and treatment of various viral infections.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Multivirus-specific T cells Dose Level 3 |
|---|---|
| Sponsor | AlloVir |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation (PHASE1)
- Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (PHASE1, PHASE2)
- Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT (PHASE1, PHASE2)
- Anti-SARS Cov-2 T Cell Infusions for COVID 19 (PHASE1)
- CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) (PHASE1)
- Multivirus-specific Cytotoxic T Lymphocytes (mCTL) (PHASE1)
- ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus (PHASE1, PHASE2)
- Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multivirus-specific T cells Dose Level 3 CI brief — competitive landscape report
- Multivirus-specific T cells Dose Level 3 updates RSS · CI watch RSS
- AlloVir portfolio CI
Frequently asked questions about Multivirus-specific T cells Dose Level 3
What is Multivirus-specific T cells Dose Level 3?
Who makes Multivirus-specific T cells Dose Level 3?
What development phase is Multivirus-specific T cells Dose Level 3 in?
Related
- Manufacturer: AlloVir — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing